Paul Peter Tak
Paul Peter Tak is a business leader, academic, entrepreneur and clinician who has over 30 years’ experience in medicine as a prominent expert in Immunology, Internal Medicine, and Rheumatology. Paul Peter is currently the President, CEO, and Board Director of Candel Therapeutics, the Co-Founder and Board Director of Sitryx Therapeutics, and Board Director of Levicept and Citryll.
Alongside his industry career, Paul Peter has dedicated much of his life to academia and advancing our understanding in medicine. He has served as Professor of Medicine at the University of Amsterdam and holds numerous honours for his service to medicine, with a special focus on Immunology and Rheumatology.
New options are needed for early-stage #prostatecancer.
Read my thoughts in this @medcitynews article on balancing efficacy with quality of life in treatment approaches:
#ProstateCancerAwarenessMonth
@britsocimm is holding its inaugural summit! Hear from @paulpetertak, and discuss trends in immune therapy and how to drive forward immune therapies research for patient benefit.
Monday 25 - Tuesday 26 November, Cambridge.
Find out more:
On #WorldCancerResearchDay, we honor the relentless pursuit of innovation in the fight against cancer.
We're developing 2nd generation viral immunotherapies to empower the immune system to combat cancer. Join us as we push the boundaries of science and bring new hope. #WCRD2024
‘Outlier Leaders do not just adapt to market changes; they anticipate and drive them, turning disruptive challenges into strategic advantages.’
